
VaxGen Wins License for Anthrax Vaccine
Wall Street Journal; C11
[10/14/2003]
A development agreement between the U.S. Army Medical Research Institute of Infectious Diseases and VaxGen gives VaxGen worldwide rights to the development and marketing of the Institute's recombinant anthrax vaccine candidate. In exchange, the Institute will receive certain fees and royalties. The vaccine, known as rPA102, is currently undergoing the first phase of clinical testing. VaxGen is funding the development with a three-year, $80.3 million contract from the National Institute of Allergy and Infectious Diseases.
|